Pipeline Momentum Leap Therapeutics is a clinical-stage cancer-focused biotech actively developing sirexatamab and FL-501. With a small team and ongoing trials, there is a demand for specialized CROs, translational research partners, and early-phase manufacturing to accelerate program timelines.

Capital Markets The company has raised about $59M through a private investment in public equity led by notable investors, signaling ongoing financing activity and potential readiness for IR services, investor targeting, and capital-raise support solutions.

Conference Outreach Regular participation in major events such as AACR, ESMO, and JP Morgan Healthcare Conference suggests a need for medical communications, KOL engagement services, and turnkey conference presence including digital materials and booth programs.

Small Team Agility With 11-50 employees, Leap is lean and potentially seeks scalable outsourcing partners for non-core functions like regulatory affairs, data management, pharmacovigilance, and contract-based research support to maintain agility and control costs.

Digital Marketing Stack The tech stack includes Shopify and other web/e-commerce oriented tools, indicating active digital outreach and patient or partner-facing resources; opportunities exist in marketing automation, website optimization, analytics, and cloud hosting to improve digital operations.